Novo's CagriSema Achieves 25% Weight Loss in Women in Late-Stage Analysis
Novo reports 25% average weight loss for women using CagriSema in a late-stage trial analysis.
Key facts
- Novo’s CagriSema produced 25% average weight loss in ~2,300 women at 68 weeks versus 3% with placebo.
- Weight loss varied by menopausal status: 26.7% premenopausal, 24.8% perimenopausal, 23.1% postmenopausal.
- CagriSema also reduced waist circumference across all groups.
- Orforglipron, a GLP‑1 pill from Eli Lilly, achieved up to 14% weight loss in women across menopausal stages in ATTAIN‑1 and ATTAIN‑2 trials.
- Menopause can cause weight gain due to declining estrogen and slowed metabolism.
Novo said its next‑generation obesity drug, CagriSema, achieved 25% average weight loss in women in a late‑stage trial analysis. The analysis included roughly 2,300 women with obesity or overweight. The drug is a combination of semaglutide and cagrilintide, which targets the amylin pathway.
According to CNBC, the weight loss varied by menopausal status. Premenopausal women lost 26.7%, perimenopausal 24.8%, and postmenopausal 23.1% at 68 weeks. All groups saw a 3% loss with placebo.
Novo added that CagriSema reduced waist circumference in women overall and across menopause stages. The reduction was based on waist measurements taken during the trial.
Healthline reported that orforglipron, a GLP‑1 pill from Eli Lilly, achieved up to 14% weight loss in women across menopausal stages in the ATTAIN‑1 and ATTAIN‑2 trials. The studies involved 142 to 225 women per group and measured weight, waist circumference, and waist‑to‑height ratio over 72 weeks.
Menopause can cause weight gain because declining estrogen slows metabolism and reduces muscle mass. More than 86 million U.S. women are 40 or older, the age range where menopause occurs. This hormonal change makes weight loss harder for many women.
Context
Menopause often leads to weight gain because estrogen levels drop and metabolism slows. This hormonal shift can make it harder for women to maintain muscle mass and lose weight. Novo’s study focuses on this group to assess drug effectiveness.
How outlets headlined it
How this was made
Compiled by our AI newsroom from 2 independent outlets, checked by a separate AI editor against the sources. Only claims found in the sources are reported. Spot an error? Every source is linked below.
Correction or source request? simoneggert16@gmail.com
Open reader debate: Factual contributions and additions are synchronized directly in real time across all readers.
Loading contributions from cloud server…
Reader Discussion & Community Notes